Association of plasma visfatin with epicardial fat thickness and severity of coronary artery diseases in patients with acute myocardial infarction and stable angina pectoris

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 47

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RYA-18-4_007

تاریخ نمایه سازی: 11 دی 1402

Abstract:

BACKGROUND: Elevated serum visfatin levels have been reported in some chronic inflammatory diseases such as cardiovascular diseases (CVDs) and rheumatoid arthritis. The purpose of the present study was to investigate the correlation between visfatin and interleukin-۶ (IL-۶) and anthropometric, angiographic, echocardiographic, and biochemical parameters in patients with acute myocardial infarction (AMI).METHODS: In this case-control study, ۹۰ patients who were candidates for angiography were divided into the following ۳ groups: non-coronary artery disease group (non-CAD; n = ۳۰) with a history of chest pain without angiographic changes, stable angina pectoris group (SAP; n = ۳۰), and AMI group (n = ۳۰). Anthropometric, angiographic, echocardiographic, and biochemical parameters were measured in all subjects.RESULTS: The mean age of patients in the non-CAD, SAP, and AMI groups was ۶۲.۲۶ ± ۱۳.۲۴, ۶۲.۹۳ ± ۸.۳۵, and ۵۲.۸۳ ± ۱۰.۲۶ years (P < ۰.۰۰۱) respectively. The results showed that the median [interquartile range] of visfatin level was higher in the AMI group [۷ (۶.۳۰-۹.۳۰), pg/ml] compared with the SAP [۵.۸۵ (۵.۲۰-۶.۶۰); P < ۰.۰۰۱] and non-CAD [۵.۲۰ (۳.۳۰-۵.۷۰); P < ۰.۰۰۱] groups. In addition, median [interquartile range] IL-۶ levels were higher in the AMI group [۱۷.۵ (۱۶-۲۱), pg/ml] compared with the SAP [۱۵.۵۰ (۱۴-۱۸); P < ۰.۰۱] and non-CAD [۱۴ (۱۱-۱۷); P < ۰.۰۰۱] groups. Furthermore, there was a positive association between plasma level of visfatin, and epicardial fat thickness (EFT) and the Gensini score in the SAP and AMI patients. The results of multivariate linear regression analysis revealed that white blood cell ‎(WBC) count and IL-۶ were independently associated with plasma visfatin level.CONCLUSION: The current study showed an association between visfatin and EFT in AMI patients. Increased visfatin levels in patients with AMI may contribute to atherosclerosis; however, further studies should be conducted to confirm this finding.

Authors

Leli Avesta

Department of Cardiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Hossein Doustkami

Department of Cardiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Bijan Zamani

Department of Cardiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Afshin Nejati

Department of Cardiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Sajad Mousavy

School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Mohammad Reza Aslani

Lung Diseases Research Center, School of Medicine, Ardabil University of Medical Sciences, Ardabil AND Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, ...
  • Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion-injury, ...
  • Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium ...
  • Piper HM, Garcia-Dorado D, Ovize M. A fresh look at ...
  • Chandrasena LG, Peiris H, Waikar HD. Biochemical changes associated with ...
  • Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ, ...
  • Yin YQ, Luo AL, Guo XY, Li LH, Huang YG. ...
  • Altun A, Ugur-Altun B. Melatonin: Therapeutic and clinical utilization. Int ...
  • Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Reiter RJ. Prognostic value ...
  • Dominguez-Rodriguez A, Abreu-Gonzalez P. Myocardial ischemia-reperfusion injury: Possible role of ...
  • Petrosillo G, Di VN, Pistolese M, Casanova G, Tiravanti E, ...
  • Dianatkhah M, Najafi A, Sharifzadeh M, Ahmadi A, Sharifnia H, ...
  • Sokullu O, Sanioglu S, Kurc E, Sargin M, Deniz H, ...
  • Zhang Y, Wang Y, Xu J, Tian F, Hu S, ...
  • Dianatkhah M, Ghaeli P, Hajhossein TA, Karimi A, Salehiomran A, ...
  • Guo XY, Luo AL, Ren HZ, Yie TH, Huang YG. ...
  • Yoshitaka S, Egi M, Morimatsu H, Kanazawa T, Toda Y, ...
  • Yin YQ, Luo AL, Guo XY, Li LH, Ren HZ, ...
  • Zhou H, Ma Q, Zhu P, Ren J, Reiter RJ, ...
  • Bourne RS, Mills GH. Melatonin: Possible implications for the postoperative ...
  • Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, ...
  • Gogenur I, Kucukakin B, Panduro JL, Reiter RJ, Rosenberg J. ...
  • Haghjooy JS, Ziaei A, Ziaei S, Ziaei E, Mirmohammad-Sadeghi M. ...
  • Reiter RJ, Tan DX. Melatonin: A novel protective agent against ...
  • Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, ...
  • Vural EM, van Munster BC, de Rooij SE. Optimal dosages ...
  • نمایش کامل مراجع